Pilonidal Sinus Clinical Trial
Official title:
Topical Anti-Androgens in Pilonidal Sinus Disease
The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are: - Does clascoterone improve the severity of pilonidal disease as scored by a physician? - Does clascoterone improve patient symptoms due to pilonidal disease? - Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Participants will apply clascoterone or a placebo cream to the diseased area for 3 months. They will be assessed every 4 weeks for disease severity assessed by a physician viewing patient photos and a symptom-based survey. Researchers will compare participants who received clascoterone treatment to those who received placebo.
Status | Not yet recruiting |
Enrollment | 75 |
Est. completion date | December 1, 2027 |
Est. primary completion date | May 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 and above - Diagnosis of Pilonidal Disease - Willingness to comply with study procedures and availability for duration of study - Ability to apply topical medications and willing to adhere to regimen Exclusion Criteria: - Current use of any topical medication to natal cleft - Presence of pilonidal-associated abscess - Pregnancy or lactation - Allergic reaction to components of 1% clascoterone cream - Febrile illness within 7 days - Treatment with another investigational drug within three months |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Hargis A, Yaghi M, Maskan Bermudez N, Lev-Tov H. Clascoterone in the treatment of mild hidradenitis suppurativa. J Am Acad Dermatol. 2024 Jan;90(1):142-144. doi: 10.1016/j.jaad.2023.08.064. Epub 2023 Sep 2. No abstract available. — View Citation
Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. — View Citation
Kalabalik-Hoganson J, Frey KM, Ozdener-Poyraz AE, Slugocki M. Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne. Ann Pharmacother. 2021 Oct;55(10):1290-1296. doi: 10.1177/1060028021992053. Epub 2021 Feb 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physician-Assessed Disease Severity Assessment | To objectively evaluate PSD, the investigators will obtain physical measurements of disease extent (left to right, cranial to caudal) and obtain disease photographs at baseline and weeks 4, 8, and 12. Photographs will be collected, deidentified, and provided to two colorectal surgeons for scoring. Surgeons will be asked to compare each timepoint to baseline and rate the PSD severity as significantly worsened, mildly worsened, unchanged, mildly improved, or significantly improved. Discrepant evaluations between surgeons will be referred to a third blinded surgeon. Data will be collated and analyzed in two fashions: as a 6-point ordinal outcome and collapsed into a dichotomous outcome with severely worsened to no change as a negative outcome and improvement as a positive outcome. | From enrollment to the end of treatment at 12 weeks | |
Primary | Dermatology Life Quality Index | Randomized subjects will be administered the Dermatology Life Quality Index (DLQI) at baseline and at 4, 8, and 12 weeks. The DLQI is a 10-question survey scored from 0-30 that has been applied widely across multiple dermatologic conditions and covers a range of potential quality of life impacts over a weekly basis. Specifically, the DLQI inquires about the impact of skin disease on symptoms (Example: "Over the past week, how itchy, painful, or stinging has your skin been?"), daily activities, leisure, work and school, and personal relationships, as well as a question of impact of treatment ("Over the last week, how much of a problem has the treatment of your skin been?"). Subjects respond Very much, A lot, A little, or Not at all for descending scores of 3 to zero. A score at or above 10 is considered a significant impact on quality of life. | From enrollment to the conclusion of treatment at 12 weeks | |
Secondary | Subcutaneous Inflammation | The investigators anticipate that a large portion of subjects will ultimately undergo surgery. Those that undergo surgery within 4 weeks will be selected. At surgery, blinded investigators will measure the excisional defect. The investigators will then follow patients with chart review in the electronic medical record for 8 weeks postoperatively to assess for immediate wound complications. A full thickness representative sample of the excised pilonidal cyst will analyzed including: antibodies against CD3, CD4, CD8, CD68, and D79. Investigators will assess the specimens for hyperkeratosis, and follicular hyperplasia. | From 12 weeks to 16 weeks after enrollment, only in patients who undergo surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01963273 -
Video Assisted Ablation of Pilonidal Sinus
|
N/A | |
Completed |
NCT00716937 -
Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus
|
Phase 4 | |
Completed |
NCT06459739 -
Effect of Sacral Erector Spinae Plane Block on Hemorrhoid and Pilonidal Sinus Surgery
|
N/A | |
Recruiting |
NCT05474911 -
PILONIDAL SINUS: CONVENTIONAL CARE VERSUS NEGATIVE PRESSURE THERAPY.
|
N/A | |
Completed |
NCT04599517 -
The Most Frequently Preferred Surgical Method In The Treatment Of Sacrococcygeal Pilonidal Disease
|
||
Recruiting |
NCT02539693 -
Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery
|
N/A | |
Completed |
NCT01081522 -
A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds
|
N/A | |
Completed |
NCT00997048 -
Comparison Between Laying Open and Sinus Excision of Pilonidal Sinus - a Randomized Study
|
N/A | |
Not yet recruiting |
NCT04273997 -
Metronidazole Ointment in Non-healing Pilonidal Sinus Wounds
|
Phase 2 | |
Recruiting |
NCT06324656 -
The Efficacy of Combining Platelet-rich Plasma With Crystallized Phenol in Pilonidal Sinus Disease
|
N/A | |
Completed |
NCT02246192 -
Use of Plasma Rich in Growth Factors (PRGF) in Pilonidal Sinus Excision
|
N/A | |
Completed |
NCT01662765 -
Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease
|
N/A | |
Completed |
NCT06206330 -
Effect of Platelet Rich Plasma (PRP) on Healing Time in Patients Following Pilonidal Sinus Surgery
|
N/A | |
Recruiting |
NCT04217824 -
Comparison of Karydakis and Limberg Flap Treatment of Pilonidal Sinus in Adolescent. a Prospective, Randomised Study
|
N/A | |
Recruiting |
NCT03483480 -
Non-Powered Negative Pressure Wound Therapy vs Open Technique for Pilonidal Disease
|
N/A | |
Not yet recruiting |
NCT06140199 -
Comparing Minimally Invasive Treatments for Pilonidal Disease: LA POPA Trial (Laser And Pit-picking OR Pit-picking Alone)
|
N/A | |
Recruiting |
NCT06391307 -
The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children
|
N/A | |
Not yet recruiting |
NCT06406621 -
Laser Hair Depilation Darker Skin Pilonidal Disease
|
N/A | |
Completed |
NCT03923621 -
Pilonidal Excision Versus Endoscopic Surgery
|
N/A | |
Active, not recruiting |
NCT01792557 -
Crystallized Phenol Versus Transposition Flaps for Treatment of Pilonidal Disease: A Prospective Study
|
N/A |